SecBot SecBot

ALKS drug pipeline

Alkermes plc. · 5 rated drugs
$46.53
−1.1% 1-day · Nov 16
Next catalyst
2026
LUMRYZ NDA filing
Typical move on FDA news
±2.7%
1-day, median of 3 events
IV rank
53
IV 52% · HV 32%
Rated drugs
5
5 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. 2026
    LUMRYZ
    NDA filing · idiopathic hypersomnia

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available since 2015 (ARISTADA) and 2018 (ARISTADA INITIO).

ARISTADA aripiprazole lauroxil Updated Nov 4

What to watch

ARISTADA is a mature commercial asset with no upcoming binary catalyst; the stock's next major value inflection points are the orexin pipeline readouts (alixorexton Phase 3 narcolepsy data expected mid-2027). Watch ARISTADA's quarterly sales trajectory for competitive erosion signals from newer LAIs like UZEDY and Invega Hafyera, but the drug's patent protection through 2039 limits near-term generic risk.

Bull case
  • ARISTADA is a well-established, FDA-approved long-acting injectable for schizophrenia with flexible dosing (monthly, 6-week, and 2-month options), offering convenience that supports adherence vs daily oral antipsychotics.
  • Patent protection extends to approximately April 2039, providing a long runway of exclusivity with no near-term generic threat.
  • The ALPINE Phase 3b study demonstrated ARISTADA's efficacy was comparable to Invega Sustenna, providing physicians with head-to-head data to support prescribing decisions.
Bear case
  • ARISTADA net sales declined slightly year-over-year in Q2 2026 ($96.7M vs $101.3M), signaling competitive pressure in the LAI antipsychotic market from J&J's Invega Sustenna/Trinza/Hafyera, Otsuka's Abilify Maintena, and newer entrants like UZEDY.
  • Patent expiry is distant (2039) but the drug faces a mature, increasingly crowded market where differentiation is difficult; the ALPINE trial showed comparable (not superior) efficacy to Invega Sustenna.
  • Alkermes' Q3 2026 GAAP net income fell to $16.3M from $87.1M a year earlier due to higher R&D and SG&A costs from the Avadel acquisition and pipeline investment, pressuring near-term profitability.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and commercially available (FDA approved May 28, 2021). A pediatric label expansion, if supported by the ENLIGHTEN-Youth trial, would be a supplemental approval, typically 6-12 months after data submission.

LYBALVI olanzapine and samidorphan Updated Nov 4

What to watch

Watch for topline results from the ENLIGHTEN-Youth Phase 3 pediatric trial (primary completion Sep 2026, results unreported as of Nov 4). Positive data could support a label expansion into adolescents, opening a new patient segment. Separately, LYBALVI's expanded payer access (~80% of covered lives) should drive prescription volume growth into 2027, though gross-to-net adjustments are expected to rise to ~45%.

Bull case
  • LYBALVI is a differentiated product: the samidorphan component mitigates olanzapine-induced weight gain by ~37-50% versus olanzapine alone, addressing a key metabolic side effect that limits olanzapine use.
  • Q3 2026 LYBALVI net sales reached $95.9M with 18% year-over-year prescription growth, and proprietary product net sales overall grew 31% YoY to $417.3M.
  • Payer access expanded to ~80% of covered lives, which management expects to drive prescription volume acceleration into 2027.
Bear case
  • Intense competition in the atypical antipsychotic market from Caplyta (lumateperone), Vraylar (cariprazine), Rexulti (brexpiprazole), Latuda (lurasidone) and generic olanzapine limits LYBALVI's market share potential.
  • Gross-to-net adjustments are expected to rise from ~42% in Q3 2026 to ~45% in 2027 as expanded payer access comes with higher rebates, pressuring net sales growth.
  • Elevated short-sale volume (63.2% of off-exchange volume vs. a 49.9% baseline, z-score 3.15) and insider selling under 10b5-1 plans signal bearish sentiment around the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready marketed (FDA-approved 2006 for alcohol dependence; 2010 for opioid dependence)

VIVITROL naltrexone Updated Jul 8

What to watch

Watch for the January 2027 Teva generic entry, this will pressure Vivitrol's ~$457M annual revenue stream. Monitor the antitrust lawsuit (Value Drug, filed Oct 2025) which could accelerate generic competition. The stock has run ~97% from its 52-week low and trades near its high; consider whether the diversification story (LUMRYZ, alixorexton orexin agonist in Phase 3) adequately offsets the Vivitrol cliff.

Bull case
  • VIVITROL net sales grew 14% YoY to $457.3M in 2024, with Q4 2024 up 31% YoY to $134.1M, still growing nicely as a mature product (source: investor.alkermes.com).
  • Alkermes is diversifying away from Vivitrol concentration: ARISTADA ($346M), LYBALVI ($280M), and the newly acquired LUMRYZ (sleep/narcolepsy) plus alixorexton orexin agonist pipeline reduce single-drug dependence (source: marketscreener.com).
  • Analyst consensus remains broadly bullish with 19 buy/strong-buy ratings, mean price target ~$50.19, with multiple firms (Mizuho, Needham, TD Cowen, RBC) maintaining Outperform/Buy.
Bear case
  • Teva licensed to launch a generic version of Vivitrol beginning January 15, 2027, this will significantly erode ~$457M in annual revenue, a ~29% chunk of Alkermes' total (source: fiercepharma.com, PRNewswire).
  • Antitrust class-action lawsuit filed Oct 2025 by Value Drug alleging Alkermes illegally blocked generic competition could accelerate generic entry or result in financial penalties (source: Reuters, JDJournal).
  • Consistent insider selling: multiple executives (CMO Hopkinson, EVP Gaffin, Director Wright) sold shares throughout 2026, mostly via 10b5-1 plans but signaling limited insider conviction at current elevated prices.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed (FDA approved April 2023).

INVEGA HAFYERA paliperidone palmitate Updated Nov 4

What to watch

INVEGA HAFYERA has no upcoming binary catalyst for Alkermes because it is an already-approved, marketed drug generating royalties. The key date to watch is May 2030, when the royalty term expires and this revenue stream ends. For Alkermes, the more impactful near-term catalysts are its proprietary pipeline, including the ALKS 2680 orexin agonist program and LUMRYZ commercial execution.

Bull case
  • INVEGA HAFYERA provides a steady, predictable royalty revenue stream for Alkermes through May 2030, with no development cost or commercial risk to Alkermes.
  • The every-six-month dosing is the longest interval available for schizophrenia, which could drive adoption and market share growth, boosting Alkermes' royalty income.
  • The 2023 arbitration win with Janssen secured the royalty terms and also awarded back royalties, strengthening Alkermes' balance sheet.
Bear case
  • INVEGA HAFYERA is not an Alkermes-owned asset; the company has no control over pricing, marketing, or commercial strategy. Royalty income depends entirely on Janssen's execution.
  • The royalty stream has a hard end date of May 2030, creating a finite revenue tail that investors must discount.
  • Combined royalty revenue from the INVEGA family was $26.4 million in Q3 2026, a relatively small portion of Alkermes' $480.1 million total quarterly revenue, limiting the drug's impact on the stock.
● neutral
Impact
PhaseApproved
Time to marketAlready approved and marketed since 2003. No further regulatory steps pending.

RISPERDAL CONSTA risperidone Updated Nov 4

What to watch

Risperdal Consta is a mature, generic-eroding asset for Alkermes. Watch the quarterly manufacturing and royalty revenue line for continued erosion as Lupin's generic gains share. The real value drivers for ALKS are its proprietary portfolio (ARISTADA, LYBALVI, VIVITROL, LUMRYZ) and the orexin pipeline readouts expected over the next year. Risperdal Consta itself has no upcoming binary catalyst.

Bull case
  • Proven technology platform: Risperdal Consta was the first long-acting atypical antipsychotic and validates Alkermes' Medisorb microsphere delivery technology, which also underpins other partnered products (INVEGA SUSTENNA, INVEGA TRINZA, VUMERITY).
  • Manufacturing moat: Alkermes exclusively manufactures Risperdal Consta at its Wilmington, Ohio facility for Janssen, providing a steady (if declining) manufacturing revenue stream that is not easily replaced.
  • Royalty upside if manufacturing stops: If Janssen terminates the manufacturing agreement without terminating the license, the royalty rate on net sales would double from 2.5% to 5.0%, partially offsetting lost manufacturing revenue.
Bear case
  • Generic competition: Lupin received FDA approval for a generic version in September 2025 and launched in November 2025 with 180-day CGT exclusivity, directly undercutting brand sales and Alkermes' manufacturing/royalty revenue.
  • Declining revenue stream: Risperdal Consta manufacturing revenue fell $5.0 million in Q1 2026 vs prior year, and total manufacturing and royalty revenues dropped 18.1% year-over-year in Q3 2026, partly due to lumpy batch timing but also reflecting generic pressure.
  • Low royalty rate: Alkermes receives only a 2.5% royalty on Janssen's net sales of Risperdal Consta (rising to 5.0% only if Janssen terminates the manufacturing agreement without terminating the license), making it a small contributor to ALKS's overall revenue.

Other drugs in filings and trials

no drug report yet
  • LUMRYZ Next: NDA filing · 2026
  • ARISTADA INITIO KIT Last: Approval · Jun 29, 2018
  • ALKS 2680 1 trial

Past FDA events & how the stock moved

3 events
DateDrugEvent1 day5 days
May 28, 2021LYBALVIApproval+2.6%+4.2%
Jun 29, 2018ARISTADA INITIO KITApproval+2.7%+6.1%
Oct 5, 2015ARISTADAApproval−3.3%−2.3%

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
ALKS 2680A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)Phase 2Completed92Jun 19, 2025